Chapter 13.10

Triple Agonist vs Dual

The breakthrough of triple-receptor activation. Analyzing Dual Agonism vs Triple Agonism metabolic yields.

Triple G

Retatrutide

Tirzepatide

Agonist Evolution

Tirzepatide: The Standard

-20.9%Weight Loss (72w)

Dual Pathway

GLP-1 + GIP co-agonism; FDA approved since 2022

Nausea Mitigation

GIP activation offsets standard GLP-1 side effects

Proven Safety

5+ years of long-term data in both T2D and Obesity

Retatrutide: The Frontier

-24.2%Weight Loss (48w)

Triple Agonism

GLP-1 + GIP + Glucagon (Triple G) activation

Metabolic Acceleration

Glucagon increases resting energy expenditure by ~15%

Experimental

Phase 3 trials ongoing; projected FDA approval Q4 2026

Attribute

Retatrutide

GGG Tri-Agonist (GLP-1/GIP/Glucagon)

Tirzepatide

Dual GIP/GLP-1 Agonist

Key Benefits

Retatrutide

Extreme weight loss (>25%)
Liver fat reduction
Metabolic rate increase

Tirzepatide

Superior Weight Loss to GLP-1 Alone
Metabolic Flexibility
Lipid Profile Improvement

Common Side Effects

Increased heart rate
Heart palpitations
Nausea

Gastrointestinal Distress
Decreased Appetite (Extreme)
Fatigue

Research Citations

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023)

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022)

Mechanical Breakthrough

Triple G Mechanism

RECEPTOR 1

GLP-1

The "Appetite Governor". Delays gastric emptying and triggers central satiety in the hypothalamus.

RECEPTOR 2

GIP

The "Metabolic Buffer". Enhances post-prandial insulin response while mitigating GLP-1 induced nausea.

RECEPTOR 3 (NEW)

GLUCAGON

The "Energy Thermostat". Increases lipid oxidation and resting energy expenditure cuerpo-wide.

Glucagon Yield (Preferential Lipolysis)

Unlike mono-agonists, Retatrutide's glucagon component essentially "instructs" the liver to preferentially burn fat while increasing body temperature and metabolic rate.

Metabolic Delta

+15.2%

Which Should You Choose?

Choose Tirzepatide If:

→You want to start NOW (FDA-approved, widely available)
→You have insurance coverage (Mounjaro/Zepbound covered)
→You want proven long-term data (5+ years of trials)
→20% weight loss is sufficient for your goals
→Lower cost ($350-400/month compounded vs. $500+ for Retatrutide)

Choose Retatrutide If:

→You want MAXIMUM weight loss (24%+ potential)
→You've plateaued on Tirzepatide or Semaglutide
→You want metabolic boost (glucagon = higher energy expenditure)
→You're OK with research chemical status (not yet FDA-approved)
→Budget allows ($500-600/month from compounding pharmacies)

Clinical Safety Alert

Non-Approved Warning

Retatrutide remains an investigational compound. While Phase 2 results are unprecedented, the lack of Phase 3 completion means long-term systemic effects on heart rate and hepatic stability are still being documented.

Not FDA Approved

Experimental Status

Gray Market Supply

Heart Rate Delta (+5-10bpm)

Availability Status

Official Ph3 FinishQ4 2025

Retail Launch Est.Q1 2027

Trial Progress: 65% Complete

Access Logic

Procurement Timeline

Standard: Tirzepatide

ChannelPharmacy (Brand) & Licensed Compounding
Cost retail$1,050 - $1,300 Monthly
Cost Compound$350 - $400 Monthly
AssuranceFDA Verified Purity & Safety Data

EXPERIMENTAL

Future: Retatrutide

ChannelLimited Compounding & Research Supply
Cost Est.$500 - $700 Monthly
FDA DecisionExpected Q4 2026 (Investigation Pending)
AssuranceThird-party COA Mandatory

🔗 Related Tools

Previous: MK-677 vs Injectables

← Chapter 13.9

Next: Myostatin Inhibitors

Chapter 13.11 →

Metabolic Hub

Triple G Protocol

Loading dashboard...

Triple G Mechanism

RECEPTOR 1

GLP-1

The "Appetite Governor". Delays gastric emptying and triggers central satiety in the hypothalamus.

RECEPTOR 2

GIP

The "Metabolic Buffer". Enhances post-prandial insulin response while mitigating GLP-1 induced nausea.

RECEPTOR 3 (NEW)

GLUCAGON

The "Energy Thermostat". Increases lipid oxidation and resting energy expenditure cuerpo-wide.

Glucagon Yield (Preferential Lipolysis)

Unlike mono-agonists, Retatrutide's glucagon component essentially "instructs" the liver to preferentially burn fat while increasing body temperature and metabolic rate.

Metabolic Delta

+15.2%

Which Should You Choose?

Choose Tirzepatide If:

→You want to start NOW (FDA-approved, widely available)
→You have insurance coverage (Mounjaro/Zepbound covered)
→You want proven long-term data (5+ years of trials)
→20% weight loss is sufficient for your goals
→Lower cost ($350-400/month compounded vs. $500+ for Retatrutide)

Choose Retatrutide If:

→You want MAXIMUM weight loss (24%+ potential)
→You've plateaued on Tirzepatide or Semaglutide
→You want metabolic boost (glucagon = higher energy expenditure)
→You're OK with research chemical status (not yet FDA-approved)
→Budget allows ($500-600/month from compounding pharmacies)

Procurement Timeline

Standard: Tirzepatide

ChannelPharmacy (Brand) & Licensed Compounding
Cost retail$1,050 - $1,300 Monthly
Cost Compound$350 - $400 Monthly
AssuranceFDA Verified Purity & Safety Data

EXPERIMENTAL

Future: Retatrutide

ChannelLimited Compounding & Research Supply
Cost Est.$500 - $700 Monthly
FDA DecisionExpected Q4 2026 (Investigation Pending)
AssuranceThird-party COA Mandatory

Peptide Assistant

Command Center BETA

Learning Journey

Tirzepatide: The Standard

Retatrutide: The Frontier

Key Benefits

Common Side Effects

Research Citations

Triple G Mechanism

GLP-1

GIP

GLUCAGON

Glucagon Yield (Preferential Lipolysis)

Which Should You Choose?

Choose Tirzepatide If:

Choose Retatrutide If:

Non-Approved Warning

Availability Status

Procurement Timeline

Standard: Tirzepatide

Future: Retatrutide

🔗 Related Tools

Tirzepatide: The Standard

Retatrutide: The Frontier

Key Benefits

Common Side Effects

Research Citations

Triple G Mechanism

GLP-1

GIP

GLUCAGON

Glucagon Yield (Preferential Lipolysis)

Which Should You Choose?

Choose Tirzepatide If:

Choose Retatrutide If:

Non-Approved Warning

Availability Status

Procurement Timeline

Standard: Tirzepatide

Future: Retatrutide

🔗 Related Tools

Command Center
BETA